Buccal Cell Cytokeratin 14 Identifies Mild Cognitive Impairment And Alzheimer’s Disease In The AIBL Study Of Aging

Document Type

Journal Article

Publisher

Bentham Science Publishers B.V.

Faculty

Faculty of Health, Engineering and Science

School

School of Medical Sciences / Centre of Excellence for Alzheimer's Disease Research and Care

RAS ID

21503

Comments

R Leifert, W., Ferdoush Tuli, J., Francois, M., Nguyen, T., Rembach, A., L Rumble, R., ... & F Fenech, M. (2015). Buccal Cell Cytokeratin 14 Identifies Mild Cognitive Impairment and Alzheimer’s Disease in the AIBL Study of Aging. Current Alzheimer Research, 12(3), 233-241. Available here

Abstract

Previous studies have suggested that mild cognitive impairment (MCI) may be reflective of the early stages of neurodegenerative disorders such as Alzheimer’s disease (AD). The hypothesis was that cytokeratin (CK) 14 expression can be used as a biomarker in isolated buccal mucosa to identify individuals with MCI or AD from the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging. Visual assessment of buccal cell CK14 expression was carried out using immunofluorescence techniques. The frequency of basal buccal cells expressing CK14 was significantly lower in the MCI (P=0.0002) and AD (P

DOI

10.2174/1567205012666150302154650

Access Rights

subscription content

Link to Full Text

Share

 
COinS